British National Formulary July 2024 Update

This update contains 8 significant changes, 2 new monographs and 1 deleted monograph.

Significant Changes:

• Borderline substances: products suitable for additional energy, protein, or fibre requirements have been moved to a new section called Energy, protein, and fibre fortifiers.
• Co-codamol: update to dose expression.
• Combined hormonal contraceptives: update to breast-feeding advice (see example in ethinylestradiol with norethisterone).
• Ear: updated guidance for the removal of ear wax.
• Finasteride: reminder of the risk of psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment) [MHRA/CHM advice].
• Intra-uterine contraceptive devices (copper): name change of Novaplus T 380® Ag to Eurogine T 380® Ag, and name change of Novaplus T 380® Cu to Eurogine T 380® Cu.
• Leuprorelin acetate: name change of Staladex® 10.72 mg to Staladex® 11.25 mg.
• Montelukast: reminder of the risk of neuropsychiatric reactions [MHRA/CHM advice].

New Monographs:

• Produodopa® [foslevodopa with foscarbidopa].
• Vanflyta® [quizartinib].

Deleted Monographs:

• Soybean oil.